Skip to main content
Your session has expired. Reloading...
Zuivertest

Health Assessment Report

Example

Urine drug screen · 5 biomarkers

Patient details

Name
J. de Groot
Gender
Male
Age
29 years
Date of birth
30-11-1996

Test details

Test Date
23-06-2026
Report date
25-06-2026
Location
Den Haag Centrum
Laboratory
Star-SHL

5

Total Markers

5

In Range

0

Needs Attention

Overall Assessment

Five substances tested in a single urine sample. None of the five was detected above the applied cut-off.

The analysis was carried out by LC-MS/MS. That is a confirmatory method: where an immunoassay rapid test cross-reacts with everyday medication, LC-MS/MS identifies the substance itself. A result from this method is therefore usable where a rapid test is not.

Key Findings

None of the five substances detected

Good

THC-COOH, cocaine, amphetamines, opiates and benzodiazepines all fall below the method's cut-off.

Material: urine · Method: LC-MS/MS

Informational

Liquid chromatography coupled to tandem mass spectrometry. This method identifies the substance itself rather than reacting to it, so cross-reactions with common medication do not arise.

A result covers a window, not a moment

Informational

Urine testing shows use in the days before the sample was taken, not use at the moment of sampling. The window differs by substance and by pattern of use.

Detailed Analysis

Drug Screening

Normal

All five substances tested fall below the method's cut-off and are reported as not detected.

Indicative urine detection windows, strongly dependent on dose, frequency and individual metabolism:

THC-COOH — one to three days with occasional use, up to several weeks with daily use. Cocaine — two to four days. Amphetamines — two to four days. Opiates — one to three days. Benzodiazepines — several days for short-acting, up to several weeks for long-acting variants.

These windows are indicative. A not-detected result does not exclude use outside the window.

Recommendations

1

Keep the PDF as the document itself

The PDF report states the laboratory, the method, the sampling date and the substances tested. That is what an employer, occupational physician or authority generally wants to see. A screenshot of this overview is not.

2

Declare any medication in advance

Some prescribed medication falls within the substance groups tested — codeine-containing painkillers under opiates, prescribed sleep and anxiety medication under benzodiazepines. That is not a fault in the test; it is the reason to declare it beforehand.

Next Steps

No follow-up testing is required. This report is the result.

If it is unclear how this result relates to prescribed medication, discuss it with the prescribing doctor. This report is a laboratory result and not medical advice.

Your Test Results

Drug Screening

5

What It Measures

This test detects the presence of THC-COOH (11-nor-9-carboxy-THC), the primary urinary metabolite of THC. After cannabis use, THC is metabolised in the liver and its metabolites are excreted in urine over an extended period. The test provides a qualitative result indicating whether THC metabolites are present above the assay cut-off level. THC metabolites are lipophilic and accumulate in fatty tissue, which contributes to the potentially long detection window, particularly with regular use.

Learn More About This Marker

What It Measures

This test primarily detects benzoylecgonine, the main metabolite of cocaine, in urine. Cocaine itself is rapidly metabolised and has a very short half-life, but benzoylecgonine persists in the body for a longer period, making it the preferred target for urine screening. The test provides a qualitative result indicating whether benzoylecgonine is present above the assay cut-off level.

Learn More About This Marker

What It Measures

This test detects the presence of amphetamine-type substances and their metabolites in urine. The amphetamine class includes amphetamine, methamphetamine, and MDMA, among others. The test provides a qualitative result indicating whether these substances are present above the assay cut-off level. Immunoassay screening may show cross-reactivity with structurally similar compounds. Confirmatory testing can differentiate between specific amphetamine-type substances.

Learn More About This Marker

What It Measures

This test detects the presence of opiate compounds and their metabolites in urine. The primary targets are morphine and codeine, which are the principal metabolites of natural and semi-synthetic opiates. The test provides a qualitative result indicating whether opiate metabolites are present above the assay cut-off level. It is important to note that standard opiate immunoassays may not detect synthetic opioids such as methadone, fentanyl, or tramadol, which require specific targeted tests.

Learn More About This Marker

What It Measures

This test detects the presence of benzodiazepine compounds and their metabolites in urine. The benzodiazepine class includes numerous agents such as diazepam, alprazolam, lorazepam, and oxazepam. Immunoassay screening typically targets common metabolites shared among many benzodiazepines. Some newer benzodiazepines may have lower cross-reactivity with standard immunoassays, potentially requiring confirmatory testing for accurate detection.

Learn More About This Marker

Assessed by a BIG-registered doctor

This report was prepared by a BIG-registered doctor. It does not replace a personal medical consultation. Always consult your general practitioner if you have questions.